Is It Time To Reassess InnoCare Pharma (SEHK:9969) After Its Strong One-Year Share Price Gain?

Simply Wall St.

May 08

If you are wondering whether InnoCare Pharma's current share price really reflects its potential, the starting point is understanding how the stock stacks up on value. The share price closed at HK$...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2633017353"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2633017353\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2633017353?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-05-08 01:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633017353","market":"nz","top_or_hot":-1,"title":"Is It Time To Reassess InnoCare Pharma (SEHK:9969) After Its Strong One-Year Share Price Gain?","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether InnoCare Pharma's current share price really reflects its potential, the starting point is understanding how the stock stacks up on value. The share price closed at HK$...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/is-it-time-to-reassess-innocare-pharma-sehk9969-after-its-st\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time To Reassess InnoCare Pharma (SEHK:9969) After Its Strong One-Year Share Price Gain?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time To Reassess InnoCare Pharma (SEHK:9969) After Its Strong One-Year Share Price Gain?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-08 01:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/is-it-time-to-reassess-innocare-pharma-sehk9969-after-its-st><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether InnoCare Pharma's current share price really reflects its potential, the starting point is understanding how the stock stacks up on value. The share price closed at HK$...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/is-it-time-to-reassess-innocare-pharma-sehk9969-after-its-st\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/is-it-time-to-reassess-innocare-pharma-sehk9969-after-its-st","article_id":"2633017353","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/is-it-time-to-reassess-innocare-pharma-sehk9969-after-its-st","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2633017353","pubTimestamp":1778176475,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether InnoCare Pharma's current share price really reflects its potential, the starting point is understanding how the stock stacks up on value.\nThe share price closed at HK$13.93 with returns of 0.7% over 7 days, a 10.2% decline over 30 days, an 11.4% gain year to date, and a 44.5% gain over 1 year. This gives useful context before comparing this to longer term figures like the 46.9% 3 year return and the 34.4% 5 year decline.\nRecent company developments and market...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","09969":"诺诚健华"},"translate_title":"诺诚健华医药（SEHK：9969）股价连续一年强劲上涨后，是时候重新评估它了吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"09969":0.9},"content_text":"If you are wondering whether InnoCare Pharma's current share price really reflects its potential, the starting point is understanding how the stock stacks up on value. The share price closed at HK$13.93 with returns of 0.7% over 7 days, a 10.2% decline over 30 days, an 11.4% gain year to date, and a 44.5% gain over 1 year. This gives useful context before comparing this to longer term figures like the 46.9% 3 year return and the 34.4% 5 year decline. Recent company developments and market commentary have kept InnoCare Pharma on investors' radars, as biopharma stocks tend to react strongly to pipeline progress, regulatory events, and funding updates. These types of catalysts often influence how quickly sentiment adjusts when expectations change. On Simply Wall St's valuation checks, InnoCare Pharma has a value score of 5 out of 6. The next sections will walk through the standard valuation approaches behind that score, before finishing with a framework that can help you understand the company's valuation in a more complete way.  Find out why InnoCare Pharma's 44.5% return over the last year is lagging behind its peers. AdvertisementApproach 1: InnoCare Pharma Discounted Cash Flow (DCF) Analysis A DCF model takes projections of a company’s future cash flows and then discounts them back to today using a required return, giving an estimate of what the equity might be worth right now. For InnoCare Pharma, the latest twelve month free cash flow is a loss of CN¥183.1m. Despite that, analysts and model assumptions project free cash flow turning positive, with CN¥400.0m in 2026 and CN¥1,366.5m by 2030. Beyond the analyst horizon, Simply Wall St extends these forecasts through to 2035 using its 2 Stage Free Cash Flow to Equity model, with each future cash flow discounted back to present value in CN¥. When all those discounted cash flows are added together, the model arrives at an estimated intrinsic value of HK$41.75 per share. Compared with the recent share price of HK$13.93, this output suggests the stock trades at a 66.6% discount to that DCF estimate. On these assumptions, the model interprets the shares as undervalued. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests InnoCare Pharma is undervalued by 66.6%. Track this in your watchlist or portfolio, or discover 221 more high quality undervalued stocks. 9969 Discounted Cash Flow as at May 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for InnoCare Pharma. Approach 2: InnoCare Pharma Price vs Earnings For profitable companies, the P/E ratio is a common way to think about what you are paying for each unit of earnings. It ties the share price directly to current profits, which many investors find easier to relate to than more technical cash flow models. What counts as a “normal” or “fair” P/E depends on how fast earnings are expected to grow and how risky those earnings are. Higher growth and lower perceived risk tend to justify a higher P/E, while slower growth or higher risk usually point to a lower P/E. InnoCare Pharma currently trades on a P/E of 28.09x, compared with the Biotechs industry average of 27.68x and a peer average of 42.35x. Simply Wall St also calculates a proprietary “Fair Ratio” for the stock of 10.12x. This Fair Ratio is designed to reflect what a reasonable P/E might be for InnoCare Pharma given factors such as its earnings growth profile, profit margins, industry, market cap and risk characteristics. Because it incorporates these company specific inputs, it can be more informative than a simple comparison with broad industry or peer averages. Comparing the current P/E of 28.09x with the Fair Ratio of 10.12x suggests the shares trade above that Fair Ratio estimate. Result: OVERVALUED SEHK:9969 P/E Ratio as at May 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 101 top founder-led companies. Upgrade Your Decision Making: Choose your InnoCare Pharma Narrative Earlier it was mentioned that there is an even better way to understand valuation, so Narratives bring your view of InnoCare Pharma together with the numbers by turning your assumptions about future revenue, earnings, margins and fair value into a clear story that links the business, a forecast and a valuation, all within an easy tool on Simply Wall St's Community page that millions of investors use. With a Narrative, you can set a fair value and then compare it with the current share price to decide whether the gap between price and value is wide enough for you, and because Narratives update when fresh information like earnings releases or trial news comes in, your view stays current rather than frozen at one point in time. For InnoCare Pharma, one investor might build a more optimistic Narrative that aligns with a higher fair value around HK$22.19 based on stronger revenue growth expectations and a future P/E of 70.7x. Another might choose a more cautious Narrative closer to HK$17.24 that assumes slower revenue growth, thinner margins and a higher future P/E of 111.9x. Comparing each Narrative's fair value with the current price can help you decide which story you think is more reasonable. Do you think there's more to the story for InnoCare Pharma? Head over to our Community to see what others are saying! SEHK:9969 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}